Arvinas Announces Poster Presentation at ASCO 2019 Genitourinary Cancers Symposium
07 févr. 2019 16h30 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that it will...
Arvinas Receives Authorization to Proceed for its IND Application for PROTAC™ Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer
04 janv. 2019 17h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that...
Arvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS)
07 déc. 2018 19h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today presented positive...
Arvinas To Present at the 30th Annual Piper Jaffray Healthcare Conference
20 nov. 2018 06h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that John G....
Arvinas to Present at Two Protein Degradation Conferences
23 oct. 2018 07h30 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced it will be...
Arvinas Announces Pricing of Initial Public Offering
26 sept. 2018 20h06 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and...